Dr. Anthony Cmelak, MD

Dr. Cmelak practices at Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center.

Dr. Cmelak's NPI, 1912099334, was assigned on September 30, 2006. Dr. Cmelak graduated from Feinberg School of Medicine in 1992. Dr. Cmelak's Tennessee license number on file is MD28099.

Dr. Cmelak's primary practice is Vanderbilt University Medical Center, at 1211 Medical Center Drive, Nashville, TN 37232 in Davidson County. The practice phone is (615) 322-3454.

Dr. Cmelak's primary practice is Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center. Dr. Cmelak is also affiliated with Williamson Medical Center. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Cmelak to 1 more hospital, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cmelak practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Cmelak's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Cmelak is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Cmelak's licenses on file in 4 states: Tennessee, California, Florida and Alabama.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Cmelak treats.

CMS data shows 3,460 Medicare services from Dr. Cmelak across 26 procedure codes in 2024, for 356 Medicare patients. Medicare paid $506,560 for them.

CMS counts 356 Medicare patients who saw Dr. Cmelak in 2024. The largest group is 65 to 74, with 172 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cmelak's median patient age at 69, with 47% women.

In 2024, Dr. Cmelak wrote 112 Medicare Part D claims for 58 patients. 88% of them were for generic drugs. CMS names the drug for 70 of them, across 5 drugs with 11 or more claims each, at $478 in total drug cost. In 2023, CMS named 25 claims across 2 drugs.

Dr. Cmelak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cmelak as offering telehealth.

Dmand AI links 110 papers to Dr. Cmelak, published from 2005 to 2024. 2016 was the busiest year, with 9. The most frequent topics are Head and Neck Neoplasms, Radiosurgery and Carcinoma, Squamous Cell. Dr. Cmelak has published most often in Int J Radiat Oncol Biol Phys. Dr. Cmelak's most frequent co-authors are Alexander Dean Sherry, MD, Albert Attia, MD and Barbara A. Murphy, MD.

Dmand AI links Dr. Cmelak to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Pain, Intractable, Squamous Cell Carcinoma of Head and Neck and Tongue Neoplasms. Vanderbilt University Medical Center sponsors the most, 2.

CMS Open Payments shows 29 general payments to Dr. Cmelak from 4 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 46% of the total. Siemens Medical Solutions USA, Inc. paid the most, $9,024.

Dmand AI lists 16 awards for Dr. Cmelak, most recently America’s Top 1% Doctors in 2016.

Dr. Cmelak graduated from Feinberg School of Medicine in 1992. Dr. Cmelak is a member of ASCO.

Dr. Cmelak is in network with 17 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.